Seeking Alpha

Regeneron (REGN) jumps 14% after disclosing that its Eylea eye drug generated $24M-25M in sales...

Regeneron (REGN) jumps 14% after disclosing that its Eylea eye drug generated $24M-25M in sales in the six weeks after November 21, slaying a Q4 anlayst forecast of $5M. Regeneron also predicted that 2012 revenue from the medicine would reach $140M-160M.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector